Since the WHI study, there has been confusion among practitioners about the safety of estrogen replacement therapy. In this presentation, Dr. Rouzier will address the evidence-based research that supports the use of oral estradiol in the treatment of menopause and how it can also reduce the risk for CVD, in addition to other unpleasant symptoms of menopause.
- Upon completion of this workshop, the healthcare professional will be able to:
- Explain what “30 heart attacks in 10,000 women” means in terms of estrogen, relative cardiac risk, and the duration of HRT therapy.
- Describe the relative risks and benefits of oral conjugated equine estrogens (Premarin) oral estradiol and transdermal estradiol for women in menopause.
- Compare the difference between the development of plaque versus plaque rupture in various stages of heart disease.
- Calculate the optimal ages to, initiate estradiol replacement therapy in women and when to discontinue estradiol replacement therapy.